DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.
Mohr E, Daniels J, Beko B, Isaakidis P, Cox V, Steele SJ, Muller O, Snyman L, De Azevedo V, Shroufi A, Trivino Duran L, Hughes J.
Mohr E, et al. Among authors: snyman l.
PLoS One. 2017 May 18;12(5):e0178054. doi: 10.1371/journal.pone.0178054. eCollection 2017.
PLoS One. 2017.
PMID: 28542441
Free PMC article.
Clinical Trial.